January 26, 2018 by CDR Blog and Chain Drug Review
cost and coverage of prescription medications, Follow The Dollar, Holly Campbell, LetsTalkAboutCost.org, Pharmaceutical Research and Manufacturers of America, PhRMA, prescription drug costs, prescription drug pricing
CDR Blog

A new website from the Pharmaceutical Research and Manufacturers of America (PhRMA) aims to give consumers a better grasp of why prescription drugs cost so much in the United States. Launched this week, the LetsTalkAboutCost.org site takes an interactive approach by engaging visitors in a Q&A about the cost and coverage of prescription medications, with a goal
December 13, 2017 by Chain Drug Review
B. Douglas Hoey, DIR fees, Examining the Drug Supply Chain, Mark Merritt, National Community Pharmacists Association, NCPA, PBM industry, Pharmaceutical Care Management Association, pharmacy benefit manager, prescription drug costs, U.S. House of Representatives Energy & Commerce Committee, video
Videos

At a health subcommittee hearing of the U.S. House of Representatives Energy & Commerce Committee, B. Douglas Hoey, CEO of the National Community Pharmacists Association (NCPA), called for legislative and regulatory action on pharmacy benefit manager (PBM) business practices to help rein in prescription drug costs. The hearing, titled “Examining the Drug Supply Chain”
October 20, 2017 by CDR Blog and Chain Drug Review
drug pricing, NASP, National Association of Specialty Pharmacy, Onco360, pharmacy industry, prescription drug costs, Tom Suozzi
CDR Blog

No one claims to hold “the solution” to soaring costs for prescription drugs and how Americans and payers — including government — can afford to pay for them. But strides toward unraveling the tangle of problems behind this issue won’t be made without determined attempts at substantive discussion between the public and private sectors, according
October 17, 2017 by Chain Drug Review
Cost of Prescription Drugs: How the Delivery System Affects What Patients Pay, DIR fees, H.R. 1038, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, Mark Merritt, National Community Pharmacists Association, Pharmaceutical Care Management Association, pharmacy benefit managers, prescription drug costs, S. 413, Senate HELP Committee, Senior Care Pharmacy Coalition
Featured Articles, Leading Headlines, Pharmacy, Retail News

WASHINGTON — Pharmacy benefit managers are a key focus of debate about elevated drug pricing that has come before a U.S. Senate committee. The National Community Pharmacists Association (NCPA) and the Senior Care Pharmacy Coalition (SCPC) called for PBM reform in written testimony submitted to a Senate Health, Education, Labor and Pensions (HELP) Committee hearing
May 18, 2017 by Chain Drug Review
Amy Klobuchar, Chuck Grassley, FAIR Drug Pricing Act, Jan Schakowsky, John McCain, Mick Mulvaney, Office of Management and Budget, prescription drug costs, prescription drug importation from Canada, prescription drug market, Safe and Affordable Drugs from Canada Act, Tammy Baldwin, Tom Price
Featured Articles, Leading Headlines, Pharmacy, Retail News

WASHINGTON — Sens. John McCain (R., Ariz.) and Tammy Baldwin (D., Wis.) and Rep. Jan Schakowsky (D., Ill.) this week reintroduced the Fair Accountability and Innovative Research (FAIR) Drug Pricing Act, aimed at improving cost transparency for pharmaceutical price hikes. The FAIR Drug Pricing Act would require drug manufacturers to notify the Department of Health
March 7, 2017 by Chain Drug Review
Austin Scott, Brian Babin, Buddy Carter, Dave Loebsack, Doug Collins, H.R. 1316, John Duncan, Mark Merritt, National Community Pharmacists Association, NCPA, PBMs, PCMA, Pharmaceutical Care Management Association, pharmacy benefit managers, prescription drug costs, Prescription Drug Price Transparency Act, video
Videos

A half-dozen congressmen pointed a finger at pharmacy benefit managers (PBMs) on the floor of the House of Representatives last week in an hour of comments on the high cost of prescriptions drugs, the National Community Pharmacists Association (NCPA) said in its Executive Update e-newsletter. In the session, Reps. Doug Collins (R., Ga.), Brian Babin
February 9, 2017 by Chain Drug Review
Alan Rosenbloom, drug price transparency, H.R. 244, MAC Transparency Act, Mark Merritt, PBM, PCMA, Pharmaceutical Care Management Association, prescription drug costs, prescription drug pricing, Rep. Doug Collins, Senior Care Pharmacy Coalition, video
Videos

With high prescription drug costs a pillar of the national debate on health care, the Pharmaceutical Care Management Association (PCMA) is trying to shed some light on drug pricing. The Washington, D.C.-based PBM trade group on Wednesday released a video titled, “What is drug price transparency?”. PCMA said the goal is to show how transparency
September 26, 2016 by Greg Jacobson and Chain Drug Review
2016 presidential election, Affordable Care Act, Donald Trump, drug pricing, generic drugs, health care, Hillary Clinton, prescription drug costs
2016, Business, Issue 09-26-2016, Issues, Leading Headlines, News, Retail News

NEW YORK — With the 2016 presidential election drawing near, health care has emerged as a policy area in which the two major candidates’ differences are strikingly clear. A useful starting point might be their respective approaches to prescription drug pricing. The Republican candidate, Donald Trump, created a sensation in January when he advocated allowing
July 25, 2016 by Geoff Walden and Chain Drug Review
ACA, Affordable Care Act, Barack Obama, health insurance, HealthCare.gov, Journal of the American Medical Association, Medicare, prescription drug costs
2016, Issue 07-25-2016, Issues, News

WASHINGTON — President Barack Obama has made suggestions for improving the Affordable Care Act (ACA), including bigger subsidies for private insurance and a Medicare-like public plan in some states. Obama also said drug makers were putting their bottom lines ahead of the common good by opposing any constraints on medication prices. “We worked successfully with
April 4, 2016 by John Schultz and Chain Drug Review
Affordable Care Act, drug spending, Express Scripts, pharmacy benefits, prescription drug costs, spending on prescription drugs
2016, Issue 04-04-2016, Issues, News, Pharmacy

WASHINGTON — Inflation in medication costs eased last year due to spending controls and fewer new blockbusters, although there are still numerous cases of sticker shock. Spending on prescription drugs rose 5.2% in 2015, including the effects of rebates, driven by an 18% increase in specialty drugs, noted Express Scripts Holding Co. in a recent
November 12, 2015 by Chain Drug Review
Aon, health care coverage, health care plan rate, prescription drug costs
CDR Blog

When it comes to health care coverage, the cost burden is continuing to shift to employees. A recent analysis by HR management consultancy Aon revealed that the average health care plan rate increase for midsize and large companies was 3.2% in 2015, the lowest rate increase since Aon began tracking the data in 1996. Aon